Aratana Therapeutics, Inc.
) received encouraging news as its canine-specific monoclonal
antibody, AT-005, gained conditional approval from the United
States Department of Agriculture (USDA), to aid the treatment of
T-cell lymphoma in dogs. Aratana shares rose on the news.
We note that conditionally approved products have a reasonable
expectation of efficacy. The conditional license for AT-005 will
expire 2 years from the date of issue.
We remind investors that Aratana acquired Vet Therapeutics in
Oct 2013. With the acquisition of Vet Therapeutics, two canine
monoclonal antibodies entered Aratana's pipeline - AT-004 (to aid
the treatment of B-cell lymphoma in dogs) and AT-005 (to aid the
treatment of T-cell lymphoma in dogs).
AT-004 gained conditional approval license from the USDA in
Nov 2012 and is expected to receive a full license in the next
12-18 months. AT-004 is licensed to
) arm, Novartis Animal Health Inc., for commercialization in U.S.
Aratana is running additional studies to support the safety
and efficacy of AT-005. For AT-005 the full product license is
expected in 2015.
AT-005 will be Aratana's first internal opportunity to
commercialize a canine lymphoma monoclonal antibody. Gaining
conditional approval is a major milestone for Aratana as it is
expected to finally commercialize its very first product this
Aratana, a biopharmaceutical company, has in-licensed three
compounds, namely, AT-001 (pain in dogs and cats), AT-002
(inappetence in dogs and cats) and AT-003 (post-surgical pain in
dogs and cats) since 2010.
We are encouraged by the company's progress with its pipeline
so far. We expect investor focus to remain on Aratana's pipeline
Aratana carries a Zacks Rank #4 (Sell). Some better-ranked
players in the pharma industry include
Forest Laboratories Inc.
). Both the stocks carry a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
FOREST LABS A (FRX): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
ARATANA THERAP (PETX): Free Stock Analysis
To read this article on Zacks.com click here.